Responses
Secondary prevention of coronary disease
Original article
High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial
Compose a Response to This Article
Other responses
No responses have been published for this article.